A major review published on September 23, 2026, found no causal link between prenatal paracetamol use and autism or ADHD, concluding that current evidence does not support changes to prescribing guidelines.
An analysis on prenatal paracetamol exposure and neurodevelopmental outcomes has found no robust evidence linking the common painkiller to autism or attention-deficit/hyperactivity disorder (ADHD). The study, published in Developmental Medicine & Child Neurology, synthesizes data from seven meta-analyses involving over 3 million participants, challenging earlier claims of a potential risk. The review was conducted by Hoda Tayebi-Hillali, María Blanco-Suárez, and Berta Rivas-Mundiña, all affiliated with the Medical-Surgical Dentistry Research Group (OMEQUI) at the Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, Spain. The study was registered in PROSPERO under the identifier CRD420251243790.
Methodological Rigor and Contradictory Findings
Tylenol during pregnancy not linked to autism, ADHD, major
The review, led by Hoda Tayebi-Hillali of the University of Santiago de Compostela, highlighted how earlier studies often lacked methodological rigor. Unrestricted analyses suggested a slight association between prenatal paracetamol use and increased autism or ADHD risk, with risk ratios of 1.17 and 1.29 respectively. However, when high-quality data was evaluated, these links disappeared. The authors wrote that methodological limitations likely influenced the observed associations between neurodevelopmental disorders and prenatal paracetamol exposure. The study’s authors emphasized that the apparent link weakened as methodological quality improved, challenging the interpretation of a causal relationship.
A separate reanalysis further questioned earlier conclusions. The study used bias-correction methods on 46 previously cited studies and found that the strong evidence of a link between paracetamol and neurodevelopmental disorders did not hold under scrutiny. For autism spectrum disorder (ASD), the association lost statistical significance after corrected weighting, while the ADHD link remained positive under some methods but not others. The reanalysis included 24 studies that reported ratio measures (hazard ratio, odds ratio, relative risk, or incidence rate ratio), with sample sizes ranging from 307 to 2,480,797. The authors applied eight bias-correction methods, a credibility ceiling analysis, and 5 quality-filtered subsets to assess the robustness of findings.
Conflicting Evidence and Overlapping Studies
Testing Claimed Associations of Prenatal Acetaminophen with Neurodevelopmental Disorders
Researchers noted significant overlap among the studies they analyzed. A review, which translated findings from a 2025 study, found that while initial meta-analyses suggested a 1.17 risk ratio for autism and 1.29 for ADHD, these figures diminished when low-quality studies were excluded. High heterogeneity and substantial overlap were observed, particularly in analyses of primary studies, the authors wrote, emphasizing that many studies reused the same data, complicating conclusions. The original umbrella review included seven meta-analyses, with 595 hits identified from six major databases up to November 2025. Of these, seven studies met inclusion criteria: three evaluated autism, and seven assessed ADHD.
The paracetamol–ADHD link is probably influenced by residual confounding and exposure misclassification, the authors wrote. The authors also noted that the overlap of primary studies—quantified using the corrected covered area—complicated the interpretation of results, as many meta-analyses reused the same datasets.
Implications for Medical Practice
42773841 Prenatal Exposure To Paracetamol And The Risk Of
The findings align with the authors’ assertion that paracetamol remains an appropriate first-line treatment during pregnancy when clinically indicated. The study’s authors stressed that untreated maternal fever or pain could pose greater risks than paracetamol use. The study concluded that, when weighing benefits against risks, existing prescribing recommendations are not supported for change by the currently available epidemiological evidence. The authors further noted that the observed associations between prenatal paracetamol exposure and neurodevelopmental disorders are likely influenced by methodological limitations, including high heterogeneity and overlapping datasets.
Despite the review’s conclusions, the authors acknowledged the need for further research. The reanalysis emphasized that methodological flaws in earlier studies may have skewed results. The original umbrella review, comprising seven meta-analyses, discovered that effect estimates were substantially attenuated and, in several models, approached the null when the analyses were limited to low-risk primary studies and higher-quality meta-analyses. For autism, the risk ratio dropped from 1.17 to 1.10 (95% CI: 0.98–1.24) after quality restrictions, while ADHD’s risk ratio remained at 1.29 but lost statistical significance under certain bias-correction methods.
A widely debated question deserves more than headlines—it deserves strong evidence, Tayebi-Hillali said in a press release. The review’s findings highlight the importance of rigorous methodology in epidemiological research, particularly for issues with significant public health implications. The authors also noted that the paracetamol–neurodevelopmental disorder link remains unproven, with current evidence not supporting a causal relationship.
Продолжение темы
